S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

Zymeworks Stock Forecast, Price & News

-1.16 (-3.10 %)
(As of 02/26/2021 07:51 PM ET)
Today's Range
Now: $36.31
50-Day Range
MA: $45.39
52-Week Range
Now: $36.31
Volume460,000 shs
Average Volume629,134 shs
Market Capitalization$1.68 billion
P/E RatioN/A
Dividend YieldN/A
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Zymeworks logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Previous SymbolNASDAQ:ZYME
Year FoundedN/A



Sales & Book Value

Annual Sales$29.54 million
Book Value$6.21 per share


Net Income$-145,440,000.00
Net Margins-569.13%


Market Cap$1.68 billion
Next Earnings Date5/6/2021 (Estimated)


Overall MarketRank

1.77 out of 5 stars

Medical Sector

157th out of 1,962 stocks

Pharmaceutical Preparations Industry

72nd out of 772 stocks

Analyst Opinion: 4.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
-1.16 (-3.10 %)
(As of 02/26/2021 07:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Zymeworks (NYSE:ZYME) Frequently Asked Questions

Is Zymeworks a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 3 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Zymeworks stock.
View analyst ratings for Zymeworks
or view top-rated stocks.

What stocks does MarketBeat like better than Zymeworks?

Wall Street analysts have given Zymeworks a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zymeworks wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Zymeworks?

Zymeworks saw a increase in short interest in February. As of February 12th, there was short interest totaling 1,590,000 shares, an increase of 111.7% from the January 28th total of 751,000 shares. Based on an average daily volume of 537,100 shares, the days-to-cover ratio is presently 3.0 days.
View Zymeworks' Short Interest

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Zymeworks

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) issued its earnings results on Wednesday, February, 24th. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.49. The business earned $15.68 million during the quarter, compared to the consensus estimate of $10.16 million. Zymeworks had a negative trailing twelve-month return on equity of 44.06% and a negative net margin of 569.13%.
View Zymeworks' earnings history

How has Zymeworks' stock been impacted by Coronavirus (COVID-19)?

Zymeworks' stock was trading at $32.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ZYME shares have increased by 12.6% and is now trading at $36.31.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ZYME?

10 analysts have issued 1 year target prices for Zymeworks' stock. Their forecasts range from $38.00 to $74.00. On average, they expect Zymeworks' share price to reach $51.11 in the next twelve months. This suggests a possible upside of 40.8% from the stock's current price.
View analysts' price targets for Zymeworks
or view top-rated stocks among Wall Street analysts.

Who are Zymeworks' key executives?

Zymeworks' management team includes the following people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 49, Pay $902.94k)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 58, Pay $578.38k)
  • Ms. Kathryn O'Driscoll, Chief People Officer (Age 57, Pay $108.89k)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 58, Pay $646.51k)
  • Dr. Neil Josephson M.D., Sr. VP of Clinical Research
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Exec. VP of Bus. Operations & CFO (Age 49)
  • Dr. Surjit Dixit, VP of Technology (Age 48)
  • Mr. Daniel Dex, VP of Legal & Corp. Sec.
  • Mr. Mark Hollywood, Sr. VP of Technical & Manufacturing Operations (Age 52)
  • Dr. Bruce Hart Ph.D., Sr. VP of Regulatory

What is Ali Tehrani's approval rating as Zymeworks' CEO?

9 employees have rated Zymeworks CEO Ali Tehrani on Glassdoor.com. Ali Tehrani has an approval rating of 100% among Zymeworks' employees. This puts Ali Tehrani in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 88.0% of employees surveyed would recommend working at Zymeworks to a friend.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by many different retail and institutional investors. Top institutional investors include Credit Suisse AG (4.00%), Morgan Stanley (3.37%), Price T Rowe Associates Inc. MD (2.60%), Lone Pine Capital LLC (2.13%), Avidity Partners Management LP (1.26%) and Wells Fargo & Company MN (1.00%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Diana Hausman, Neil A Klompas and Troy Cox.
View institutional ownership trends for Zymeworks

Which institutional investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Candriam Luxembourg S.C.A., Renaissance Technologies LLC, Alyeska Investment Group L.P., Alyeska Investment Group L.P., State of New Jersey Common Pension Fund D, Orbimed Advisors LLC, and Wells Fargo & Company MN. Company insiders that have sold Zymeworks company stock in the last year include Ali Tehrani, Diana Hausman, and Neil A Klompas.
View insider buying and selling activity for Zymeworks
or view top insider-selling stocks.

Which institutional investors are buying Zymeworks stock?

ZYME stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Lone Pine Capital LLC, Artal Group S.A., Avidity Partners Management LP, Credit Suisse AG, Price T Rowe Associates Inc. MD, K.J. Harrison & Partners Inc, and Silverarc Capital Management LLC. Company insiders that have bought Zymeworks stock in the last two years include Ali Tehrani, and Troy Cox.
View insider buying and selling activity for Zymeworks
or or view top insider-buying stocks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $36.31.

How much money does Zymeworks make?

Zymeworks has a market capitalization of $1.68 billion and generates $29.54 million in revenue each year. The company earns $-145,440,000.00 in net income (profit) each year or ($3.83) on an earnings per share basis.

How many employees does Zymeworks have?

Zymeworks employs 325 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is www.zymeworks.com.

Where are Zymeworks' headquarters?

Zymeworks is headquartered at 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]

This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.